证券记录 · 已归档季度
LXEO
Lexeo Therapeutics, Inc. Common Stock · Healthcare · Biotechnology
16被追踪持有人
+1Δ持有人
14.53M持有股份
$96.47M报告持仓市值
+1新建仓位
−0清仓
动量输入（同类管理人）：
持有人广度 +6.7% ·
股份流向 +14.7% ·
净新建仓位 +6.2%
— 公式
广泛积累 — 持股数量上升且持有人增多
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 64 | +3 | 35.14M | $163.68M | +8 | −5 |
| Q1 2026 | 64 | -1 | 34.99M | $201.02M | +4 | −5 |
| Q4 2025 | 65 | +1 | 34.14M | $338.98M | +1 | — |
| Q3 2025 | 16 | +1 | 14.53M | $96.47M | +1 | — |
| Q2 2025 | 12 | -2 | 12.40M | $49.85M | — | −2 |
| Q1 2025 | 11 | +1 | 6.39M | $22.16M | +2 | −1 |
| Q4 2024 | 10 | +3 | 6.97M | $45.84M | +3 | — |
| Q3 2024 | 6 | +1 | 6.33M | $57.26M | +1 | — |
| Q2 2024 | 5 | — | 5.51M | $88.42M | — | — |
持有人 · Q3 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Citadel Advisors ✦ | 3.72M | +3.1% | $24.69M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 3.72M | +3.1% | $24.69M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 3 | Millennium Management ✦ | 2.31M | -18.4% | $15.36M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 4 | The Vanguard Group ✦ (被动) | 2.23M | +11.2% | $14.78M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | The Vanguard Group ✦ (被动) | 2.23M | +11.2% | $14.78M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | The Vanguard Group ✦ (被动) | 2.23M | +11.2% | $14.78M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | BlackRock ✦ (被动) | 2.17M | +18.8% | $14.42M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | BlackRock ✦ (被动) | 2.17M | +18.8% | $14.42M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | BlackRock ✦ (被动) | 2.17M | +18.8% | $14.42M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | BlackRock ✦ (被动) | 2.17M | +18.8% | $14.42M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | BlackRock ✦ (被动) | 2.17M | +18.8% | $14.42M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | BlackRock ✦ (被动) | 2.17M | +18.8% | $14.42M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | BlackRock ✦ (被动) | 2.17M | +18.8% | $14.42M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | Point72 Asset Management ✦ | 1.94M | +199.7% | $12.89M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 15 | Geode Capital Management ✦ (被动) | 721.88K | +24.9% | $4.79M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 16 | Geode Capital Management ✦ (被动) | 721.88K | +24.9% | $4.79M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 17 | State Street Global Advisors ✦ (被动) | 544.85K | +6.2% | $3.62M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 18 | AQR Capital Management ✦ | 347.92K | +84.4% | $2.31M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 19 | AQR Capital Management ✦ | 347.92K | +84.4% | $2.31M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 347.92K | +84.4% | $2.31M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 21 | AQR Capital Management ✦ | 347.92K | +84.4% | $2.31M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 347.92K | +84.4% | $2.31M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 23 | Renaissance Technologies ✦ | 149.30K | +40.6% | $991,352 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 24 | Goldman Sachs Group ✦ | 142.40K | — | $945,549 | 0.0% | n/c | 1 | SEC ↗ |
| 25 | Goldman Sachs Group ✦ | 142.40K | — | $945,549 | 0.0% | n/c | 1 | SEC ↗ |
| 26 | Morgan Stanley ✦ | 98.06K | — | $651,097 | 0.0% | n/c | 1 | SEC ↗ |
| 27 | Morgan Stanley ✦ | 98.06K | — | $651,097 | 0.0% | n/c | 1 | SEC ↗ |
| 28 | Morgan Stanley ✦ | 98.06K | — | $651,097 | 0.0% | n/c | 1 | SEC ↗ |
| 29 | Morgan Stanley ✦ | 98.06K | — | $651,097 | 0.0% | n/c | 1 | SEC ↗ |
| 30 | Morgan Stanley ✦ | 98.06K | — | $651,097 | 0.0% | n/c | 1 | SEC ↗ |
| 31 | Morgan Stanley ✦ | 98.06K | — | $651,097 | 0.0% | n/c | 1 | SEC ↗ |
| 32 | Two Sigma Investments ✦ | 84.76K | +22.4% | $562,826 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 33 | JPMorgan Chase ✦ | 28.72K | — | $190,688 | 0.0% | n/c | 1 | SEC ↗ |
| 34 | JPMorgan Chase ✦ | 28.72K | — | $190,688 | 0.0% | n/c | 1 | SEC ↗ |
| 35 | JPMorgan Chase ✦ | 28.72K | — | $190,688 | 0.0% | n/c | 1 | SEC ↗ |
| 36 | JPMorgan Chase ✦ | 28.72K | — | $190,688 | 0.0% | n/c | 1 | SEC ↗ |
| 37 | Fidelity (FMR) ✦ | 13.43K | +14.3% | $89,195 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 38 | D. E. Shaw & Co. ✦ | 12.82K | 新增 | $85,112 | 0.0% | New | 1 | SEC ↗ |
| 39 | T. Rowe Price ✦ | 11.96K | +14.8% | $80,000 | 0.0% | ▲ Add | 4 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| D. E. Shaw & Co. | $85,112 | 0.0% |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 137 持有人, 79.80M 股份, $457.81M 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Aug 18
Townsend Richard Nolan
Officer, Director · 3.35K 股 · $16,562
Aug 18
Otero Jose Manuel
Officer · 1.30K 股 · $6,464
Aug 18
Tamayo Louis Edward
Officer · 4.12K 股 · $20,203
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
Aug 14
SC 13G/A — Paradigm Biocapital Advisors LP
Aug 14
SC 13G/A — BALYASNY ASSET MANAGEMENT L.P.
Aug 14
SC 13G — ORBIMED ADVISORS LLC
Aug 13
SC 13G/A — Affinity Asset Advisors, LLC
Aug 07
SC 13G — STATE STREET CORP
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q3 2025 ·
方法论 ·
通过API获取此数据